🇺🇸 FDA

Company profile · Sponsor

ATOSSA

ATOSSA THERAPEUTICS, INC.

ATOS · NYSE pharma SEATTLE, WA, USA
Pipeline
10
Drugs
0
Patents
8

Quick answer

ATOSSA (ATOS) is a pharma company. headquartered in SEATTLE, WA, USA. listed on NYSE. NovaPharmaNews links 10 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker ATOS
Exchange NYSE
Company type pharma
Headquarters SEATTLE, WA, USA
SEC CIK 0001488039

Pipeline (10)

Search pipeline →

  1. ForeCYTE Breast Aspirator

    ATOSSA

    Breast Cancer, Preneoplastic Conditions, BRCA

    phase 3 other terminated

    1 trial

  2. (Z)-endoxifen

    ATOSSA

    Breast Neoplasms

    phase 2 small molecule active

    1 trial

  3. ASCAPE-based follow-up strategy

    ATOSSA

    Breast Cancer

    phase 2 other active

    1 trial

  4. Fulvestrant

    ATOSSA

    Female Breast Carcinoma

    phase 2 small molecule terminated

    1 trial

  5. Provox Vega voice prosthesis 22.5 Fr

    ATOSSA

    Total Laryngectomy

    phase 2 other completed

    1 trial

  6. Provox voice prosthesis

    ATOSSA

    Total Laryngectomy

    phase 2 other completed

    1 trial

  7. Topical endoxifen

    ATOSSA

    Mammographic Breast Density

    phase 2 small molecule completed

    1 trial

  8. Z-Endoxifen

    ATOSSA

    Breast Density

    phase 2 small molecule completed

    1 trial

  9. AT-301B

    ATOSSA

    Healthy

    phase 1 small molecule completed

    1 trial

  10. Provox Xtra HME

    ATOSSA

    Total Laryngectomy

    phase 1 other completed

    1 trial

Patents (8)

Search patents →

  1. US 12281056

    Methods for making and using endoxifen

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12275684

    Methods for making and using endoxifen

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12201591

    Sustained release compositions of endoxifen

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12071391

    Methods for making and using endoxifen

    Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11680036

    Methods for making and using endoxifen

    Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11572334

    Methods for making and using endoxifen

    Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11261151

    Methods for making and using endoxifen

    Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 6894026

    Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders

    Expires Mon May 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is ATOSSA?

ATOSSA (ATOS) is a pharma company. headquartered in SEATTLE, WA, USA. listed on NYSE. NovaPharmaNews links 10 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does ATOSSA sponsor?

We track 10 ClinicalTrials.gov-linked programs for ATOSSA, including ForeCYTE Breast Aspirator and 9 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does ATOSSA company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.